Abstract:Cryptococcus neoformans and Cryptococcus gattii cause cryptococcosis, a life-threatening fungal infection affecting mostly immunocompromised patients. In fact, cryptococcal meningitis accounts for about 19% of AIDS-related deaths in the world. Because of long-term azole therapies to treat this mycosis, resistance to fluconazole leading to treatment failure and poor prognosis has long been reported for both fungal species. Among the mechanisms implicated in resistance to azoles, mutations in the ERG11 gene, encoding the azole target enzyme lanosterol 14-α-demethylase, have been described. This study aimed to establish the amino acid composition of ERG11 of Colombian clinical isolates of C. neoformans and C. gattii and to correlate any possible substitution with the in vitro susceptibility profile of the isolates to fluconazole, voriconazole, and itraconazole. Antifungal susceptibility testing results showed that C. gattii isolates are less susceptible to azoles than C. neoformans isolates, which could correlate with differences in the amino acid composition and structure of ERG11 of each species. In addition, in a C. gattii isolate with high MICs for fluconazole (64 μg/mL) and voriconazole (1 μg/mL), a G973T mutation resulting in the substitution R258L, located in substrate recognition site 3 of ERG11, was identified. This finding suggests the association of the newly reported substitution with the azole resistance phenotype in C. gattii. Further investigations are needed to determine the exact role that R258L plays in the decreased susceptibility to fluconazole and voriconazole, as well as to determine the participation of additional mechanisms of resistance to azole drugs. IMPORTANCE The fungal species Cryptococcus neoformans and C. gattii are human pathogens for which drug resistance or other treatment and management challenges exist. Here, we report differential susceptibility to azoles among both species, with some isolates displaying resistant phenotypes. Azoles are among the most commonly used drugs to treat cryptococcal infections. Our findings underscore the necessity of testing antifungal susceptibility in the clinical setting in order to assist patient management and beneficial outcomes. In addition, we report an amino acid change in the sequence of the target protein of azoles, which suggests that this change might be implicated in resistance to these drugs. Identifying and understanding possible mechanisms that affect drug affinity will eventually aid the design of new drugs that overcome the global growing concern of antifungal resistance.

[Cloning and Sequencing of the GTP Cyclohydrolase I Function Region of Azole Target Enzyme Gene in Artificially Induced Resistant Candida Albicans].

Advances in the study of Candida albicans gene mutation on azole drug resistance]

The relationship between ERG11 gene mutation of Candida albicans and fluconazole-resistance

Resistant Mechanisms of Candida albicans to Azoles

Erg11 Mutations Associated with Azole Resistance in Clinical Isolates of Candida Albicans.

ERG11 mutations and expression of resistance genes in fluconazole-resistant Candida albicans isolates

The Point Mutation of Cytochrome P-450 Lanosterol 14-Α Demethylase ERG11 Gene in Fluconazole-resistant Candida Albicans

Study of Azole Resistant Mechanisms of Candida albicans

Mutation Hotspot of CYP51 of Candida Albicans to Azole Resistance

Erg 11 mutations associated with azole resistance in clinical isolates of Candida albicans Running title : Erg 11 mutations in Candida albicans

Analysis of ERG11 gene mutations in fluconazole-resistant Candida glabrata strains

Study on mechanisms of zole-resistance of clinical Candida glabrata isolates

Relationship Between Antifungal Resistance of Fluconazole Resistant Candida Albicans and Mutations in Erg11 Gene

Mutation of P927S in PRD1 gene mediates azole resistance in Candida glabrata

DNA Microarray Analysis of Fluconazole Resistance in a Laboratory Candida Albicans Strain.

Induction of Fluconazole Resistance in Candida Glabrata and Candida Parapsilosis in Vitro and Corresponding Mechanism

Susceptibility Of Clinical Isolates Of Candida Species To Fluconazole And Detection Of Candida Albicans Erg11 Mutations

Reduced Susceptibility to Azoles in Cryptococcus gattii Correlates with the Substitution R258L in a Substrate Recognition Site of the Lanosterol 14-α-Demethylase

Mechanism of fluconazole resistance of Candida tropicalis in clinical isolates

Gene Expression Analysis of Key Players Associated with Fluconazole Resistance in Candida Albicans

Candida albicans gains azole resistance by altering sphingolipid composition